Haleos Labs share news, announcements and annual reports
NSE: HALEOSLABSBSE: 540679Pharmaceuticals & BiotechnologySmall Cap
HALEOS LABS LIMITED · Formerly SMS Lifesciences India · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2017
Last close ₹1,394.40down ₹34.80 (2.43%)BSE ₹1,359.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,429.20.
30 Oct: open ₹1,426.10, high ₹1,430.00, low ₹1,382.00
52-week range of traded prices to 30 Oct 2026
₹1,091.10Low, 30 Jan 2026₹1,774.00High, 11 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹422 Cr1,954th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.68
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.97
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,40775.8% delivered
Haleos Labs disputes and clarifications
19 filed, newest first.
Apr 2022
12 Apr · Legal
The exchange asked on 11 Apr 2022
Dec 2021
1 Dec · Legal
Exchange has sought clarification from SMS Lifesciences India Limited with respect to announcement dated 30-Nov-2021, regarding approval of issue of shares in the Board meeting held on November 30, 2021. On basis of above the Company is required to clarify following: 1. Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);The response of the Company is awaited.
Oct 2021
30 Oct · Legal
The exchange asked on 29 Oct 2021
Jul 2021
Jun 2021
26 Jun · Legal
Exchange has sought clarification from SMS Lifesciences India Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Apr 2021
8 Apr · Legal
Significant movement in price has been observed in SMS Lifesciences India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Sep 2020
24 Sep · Legal
The exchange asked on 23 Sep 2020
Aug 2020
Jul 2020
31 Jul · Legal
Exchange has sought clarification from SMS Lifesciences India Limited with respect to announcement dated 28-Jul-2020, regarding ' appointment of Internal Auditor pertaining to Regulation 30 (6) read with sub-para 7 of para "A" of part "A" of Schedule 111 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and SEBI circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Jun 2020
12 Jun · Legal
The exchange asked on 11 Jun 2020
Apr 2020
17 Apr · Legal
The exchange asked on 16 Apr 2020
Sep 2019
17 Sep · Legal
The exchange asked on 16 Sep 2019
Aug 2019
12 Aug · Legal
The exchange asked on 9 Aug 2019
Jun 2019
May 2019
31 May · Legal
Exchange has sought clarification from SMS Lifesciences India Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Jan 2019
10 Jan · Legal
The exchange asked on 9 Jan 2019
4 Jan · Legal
The exchange asked on 3 Jan 2019